| This week's sponsor is Premier Research. | |  | Rare Cancer Drug Research: What to Know Going In
Rare cancer drug research requires oncology and rare disease expertise and careful attention to trial design and regulatory demands. Get started with our white paper. Premier Research. It's what we do. Best. |
Today's Rundown | Publisher’s Note: In preparation for the new GDPR taking effect this month, we would like to reconfirm your subscription to our newsletter(s). Please click this link to reconfirm your subscription. For more information about GDPR, please visit this page. | |
|
Featured Story | | | Thursday, May 24, 2018 Armed with a trio of partnerships and $260 million in the bank, Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China. |
|
|
Top Stories Thursday, May 24, 2018 Bloom Science has raised seed money and licensed technology to treat CNS diseases via the gut-brain axis. Building on research into the ketogenic diet, Bloom is initially focusing on developing bacterial treatments for epilepsy. Wednesday, May 23, 2018 Astellas Pharma has begun restructuring its operations, with plans to discontinue all work at its R&D subsidiary of about 200 employees by March 2019. An early retirement incentive program is estimated to cut 600 staff altogether, in the face of exclusivity losses expected to cause a dip in operating profits next year. Monday, May 21, 2018 Progress has been made in developing medicines for children with the passing of pediatric regulation, but gaps still exist. Here’s what you need to know about recent updates from an expert at Synteract. Thursday, May 24, 2018 With the ink barely dry on a partnership deal with Allergan, Aptinyx has announced plans for an $80 million IPO to accelerate work on its drugs for neurological disorders. Thursday, May 24, 2018 Novo Nordisk has picked up the worldwide rights to a kidney disease drug in development at Epigen. The agreement gives Novo control of orally available LPA1 receptor antagonist EPGN696 in exchange for up to $200 million in upfront and milestone payments. Thursday, May 24, 2018 Curis is bringing on board member Robert Martell as a full-time employee in the newly created role of head of R&D. Martell was formerly chief medical officer at Tesaro, after serving as director of global oncology research at Bristol-Myers Squibb. | This week's sponsor is IQVIA. | |  | |
Resources Sponsored by: Seton Hall Law 4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics. Presented by: Patheon There are many parenteral dosage forms from which the pharmaceutical scientist can choose to develop their drug product. In this article, the author discusses the choices available and strategies which can be employed at the different stages of development. Sponsored by: Veeva Systems Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems. Sponsored by: Veeva Systems UCB took a more holistic approach to managing regulatory processes. Read how their efforts are paying off. Sponsored by: Veeva Systems Find out how to eliminate regulatory’s tracking spreadsheets for good. Sponsored by: Veeva Systems Learn how cloud-enabled solutions provide real-time insights and actionable analytics to improve clinical trial safety and performance in this short presentation. Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. | 
